Abstract
This article reviews the progress of nanoparticles as drug carriers in the treatment of cardiovascular diseases, and how nanoparticles can deliver anti-inflammatory, anti-proliferative, and anticoagulant drugs directly to the surgical site in surgical procedures. For this, 45 articles published between 2005 and 2024 with keywords including "Artificial intelligence Nanoparticle", "Emergency Medicine Unit", and "Therapeutic for the treatment of cardiovascular diseases" in Scopus, Elsevier, Web of Science and ScienceDirect were reviewed. Nanoparticle-based drug delivery systems have demonstrated several noteworthy therapeutic benefits in the treatment of cardiovascular disorders since they were first used in the cancer field to deliver safer and more effective chemotherapeutics. By delivering targeted and site-specific medications with controlled release, nanoparticle-based drug delivery systems modify the biodistribution of therapeutic agents. An optimal material for cardiovascular therapeutics would be a nanoparticle based on metal, lipid, or polymer.